Role of formulation vehicles in taxane pharmacology

被引:260
作者
van Zuylen, L
Verweij, J
Sparreboom, A
机构
[1] Rotterdam Canc Inst, Daniel den Hoed Klin, Dept Med Oncol, NL-3008 AE Rotterdam, Netherlands
[2] Univ Rotterdam Hosp, Rotterdam, Netherlands
关键词
Cremophor EL; paclitaxel; Tween; 80; docetaxel; pharmacokinetics;
D O I
10.1023/A:1010618632738
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The non-ionic surfactants Cremophor EL (CrEL) and Tween 80, both used as formulation vehicles of many (anticancer) agents including paclitaxel and docetaxel, are not physiological inert compounds. We describe their biological properties, especially the toxic side effects, and their pharmacological properties, such as modulation of P-glycoprotein activity. In detail, we discuss their influence on the disposition of the solubilized drugs, with focus on CrEL and paclitaxel, and of concomitantly administered drugs. The ability of the surfactants to form micelles in aqueous solution as well as biological fluids (e.g. plasma) appears to be of great importance with respect to the pharmacokinetic behavior of the formulated drugs. Due to drug entrapment in the micelles, plasma concentrations and clearance of free drug change significant leading to alteration in pharmacodynamic characteristics. We conclude with some perspectives related to further investigation and development of alternative methods of administration.
引用
收藏
页码:125 / 141
页数:17
相关论文
共 153 条
  • [41] Fujimoto S, 1994, Gan To Kagaku Ryoho, V21, P665
  • [42] Fumoleau P, 1998, ANN ONCOL, V9, P101
  • [43] GANTT CL, 1961, LANCET, V1, P486
  • [44] Gehl J, 1996, ANN ONCOL, V7, P687
  • [45] Gelderblom H, 1999, DRUG METAB DISPOS, V27, P1300
  • [46] NONLINEAR PHARMACOKINETICS AND METABOLISM OF PACLITAXEL AND ITS PHARMACOKINETIC/PHARMACODYNAMIC RELATIONSHIPS IN HUMANS
    GIANNI, L
    KEARNS, CM
    GIANI, A
    CAPRI, G
    VIGANO, L
    LOCATELLI, A
    BONADONNA, G
    EGORIN, MJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (01) : 180 - 190
  • [47] Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer
    Gianni, L
    Vigano, L
    Locatelli, A
    Capri, G
    Giani, A
    Tarenzi, E
    Bonadonna, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) : 1906 - 1915
  • [48] PACLITAXEL BY 3-HOUR INFUSION IN COMBINATION WITH BOLUS DOXORUBICIN IN WOMEN WITH UNTREATED METASTATIC BREAST-CANCER - HIGH ANTITUMOR EFFICACY AND CARDIAC EFFECTS IN A DOSE-FINDING AND SEQUENCE-FINDING STUDY
    GIANNI, L
    MUNZONE, E
    CAPRI, G
    FULFARO, F
    TARENZI, E
    VILLANI, F
    SPREAFICO, C
    LAFFRANCHI, A
    CARACENI, A
    MARTINI, C
    STEFANELLI, M
    VALAGUSSA, P
    BONADONNA, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (11) : 2688 - 2699
  • [49] Goldspeil BR, 1995, PACLITAXEL CANC TREA, P175
  • [50] HACKER M, 1981, RES COMMUN CHEM PATH, V31, P119